Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025 ...

Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical ...

Detailed price information for Xoma Corp 8.625% (XOMAP-Q) from The Globe and Mail including charting and trades.

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Xoma Royalty has agreed to acquire HilleVax. Emeryville, Calif.-based Xoma plans to begin a tender offer for the Boston vaccine developer by Aug. 18, the biotechnology-royalty aggregator said Monday.

XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Xoma Royalty has agreed to acquire Lava Therapeutics.

The filing shows HilleVax had $124.5 million in cash at the end of 2021. Combined with the IPO cash, the company said it plans to spend about $125 million on clinical development of its norovirus ...